What Do Fundamentals Tell About This Stock-TEM

Acrobull Canada Advisory Inc.

April 11			2025
Name	Ticker	Sector/Industry		Market Cap	Risk Factor
Tempus AI Inc.	NASDAQ-TEM	Technology		$6.971 Billion	Medium

Tempus AI, Inc. is a healthcare technology business. It offers next-generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology tests to healthcare practitioners, pharmaceutical firms, biotechnology companies, researchers, and other third parties.

Recent Highlights

Tempus Announces Acquisition of Deep 6 AI- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.

Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data across a broad ecosystem, which includes academic medical centers.

Fourth Quarter 2024 Highlights

Quarterly revenue climbed by 35.8% year on year to $200.7 million in the fourth quarter of 2024.

Genomics earned $120.4 million in sales in the fourth quarter of 2024, a 30.6% year-over-year increase, with unit growth of 22.5% year over year.

Data and services earned $80.2 million in sales in the fourth quarter of 2024, up 44.6% year on year.

Quarterly gross profit climbed by 49.7% to $122.1 million, with data and services leading the way.

Adjusted EBITDA increased to $7.8 million in the fourth quarter of 2024, from $35.1 million in the fourth quarter of 2023 and $21.8 million in the third quarter of 2024.

Stock Observation- The company has reported stable financial results in the fourth quarter of 2024 and is expected to do well since it is one of the best-performing Health-tech stocks in the industry. The RSI level for the stock is at 39, which shows oversold conditions.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull Canada Advisory Inc. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrobull Canada Advisory Inc. only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrobull Canada Advisory Inc. would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull Canada Advisory Inc. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull Canada Advisory Inc. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$40.29 USD
Acrobull Recommendation	Buy
Target Price	$46.21 USD
RSI Level	14 Day RSI 39
Total Shares Outstanding	167.99 Million
Shares held by Insiders Risk Factor Stop Loss	47.67% Medium 5%